To conduct a retrospective evaluation of tetrahydropyranyladriamycin (PIR)-based combination chemotherapy for osteosarcomas in comparison with doxorubicin (DOX)-based regimens to determine differences in response and toxicities between DOX- and PIR-containing regimens.
METHODS:
Toxicities and response rates of the 2 anthracyclines given as combination chemotherapy were assessed in patients with osteosarcoma, with 19 patients receiving PIR-based and 11 receiving DOX-based regimens.
RESULTS:
The survival of osteosarcoma patients treated with PIR was significantly better than that with DOX (p = 0.023) based on 2-year follow-up. Adverse effects such as mucositis and diarrhea were also less pronounced in the PIR cohort.
CONCLUSIONS:
PIR-based combination chemotherapy might be a useful and safe chemotherapeutic strategy for osteosarcomas compared with DOX regimens. Further assessment is necessary to confirm the safety and efficacy of this treatment.
EnnekingWFSpanierSSGoodmanMA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop1980;153: 106–20.
2.
SouhamiRLCraftAWVan der EijkenJWNooijMSpoonerDBramwellVHRandomised trial of two regimens of chemotherapy in operable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet1997;350: 911–7.
3.
BacciGMercuriMBriccoliAFerrariSBerotoniFDonatiDOsteogenic sarcoma of the extremity with detectable lung metastases at presentation: Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesion. Cancer1997;79: 245–54.
4.
RosenGCaparrosBHuvosAGKosloffCMirenbergACacavioAPreoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer1982;49: 1221–30.
5.
O'BryanRMLuceJKTalleyRWGottliebJABakerLHBonadonnaG. Phase II evaluation of adriamycin in human neoplasia. Cancer1973;32: 1–8.
6.
TanCEtcubanasEWollnerNRosenGGilladogaAShowelJAdriamycin — An antitumor antibiotic in the treatment of neoplastic diseases. Cancer1973;32: 9–17.
7.
SridharKHusseinAHBenedettoPArdalanBSavarajNRichmanSP. Phase II trial of 4′-O-tetrahydropyranyladriamycin (Pirarubicin) in head and neck carcinoma. Cancer1992;70: 1591–7.
8.
TakagiTSakaiCOguroM. Combination chemotherapy with pirarubicin (THP), cyclophosphamide, vincristine, and prednisolone (VEPTHP therapy) in the treatment of non-Hodgkin's lymphoma. Oncology1990;47: 25–8.
9.
EnomotoKAbeOTominagaTAbeRIinoYKoyamaHClinical study of Pirarubicin for breast cancer in Japan. Am J Clin Oncol1990;13(suppl 1):S48–53.
10.
HeraitPPoutignatNMartyMBugatR. Early assessment of a new anticancer drug analogue — Are the historical comparisons obsolete? The French experience with pirarubicin. Eur J Cancer1992;28A:1670–6.
11.
Toxic effects. WHO handbook for reporting results of cancer treatment. No. 48. WHO offset publication. Geneva, Switzerland: World Health Organization, 1979: 14–21.
12.
PounaPBonoronASGouverneurGTariosseLBessePRobertJ. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: Comparison of new analogues versus doxorubicin. Cancer Chemother Pharmacol1995;35: 257–61.
13.
HiranoSWakazonoKAgataNIguchiHToneH. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res1994;20: 153–60.
14.
OkadaYHorikawaKSanoM. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy.] Japanese. Gan To Kagaku Ryoho1997;24: 585–9.
15.
Stuart-HarrisRCHarperPGParsonsCAKayeSBMooneyCAGowingNFHigh-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol1983;11: 69–72.
16.
MartiCKronerTRemagenWBerchtoldWCserhatiMVariniM. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep1985;69: 115–7.
17.
BenjaminRSLeghaSSPatelSRNicaiseC. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: The M.D. Anderson experience. Cancer Chemother Pharmacol1993;31(suppl 2):S174–9.
18.
BokemeyerCFranzkeAHartmannJSchoberCArsenievLMetznerBA Phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer1997;80: 1221–7.
19.
BohannonRAMillerDGDiamondHD. Vincristine in the treatment of lymphomas and leukemias. Cancer Res1963;23: 613–21.
20.
PilepichMVViettiTJNesbitMETefftMKissaneJBurgertEORadiation and combination chemotherapy in advanced Ewing's sarcoma — Intergroup study. Cancer1981;47: 1930–6.
21.
DaugaardSSundeLMKambyCSchiodtTJensenOM. Ewing's sarcoma. A retrospective study of prognostic factors and treatment results. Acta Oncol1987;26: 281–7.
22.
KaplanELMeierP. Nonparametric estimation from incomplete observations. J Am Statist Assoc1958;53: 457–81.
23.
TaylorWFIvinsJCDahlinDCEdmonsonJHPritchardDJ. Trends and variability in survival from osteosarcoma. Mayo Clin Proc1978;53: 695–700.
